Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 25th Preview)
-
Alzheimer’s blood-based diagnostics gain FDA validation
Roche and Eli Lilly won U.S. FDA clearance for the Elecsys pTau217 Plasma blood test, enabling clinicians to rule in and rule out Alzheimer’s disease in adults 55 and older presenting with cognitive decline. The assay targets phosphorylated tau (pTau217), linked to amyloid plaque pathology, and is designed for use with Roche’s Cobas lab instruments. The clearance comes as the Alzheimer’s blood-testing landscape heats up: Labcorp and Quest said they plan to offer the test, and the FDA has cleared other pTau and amyloid-related assays earlier in 2025 and 2026. Roche said the pTau217 test uses validated clinical cutoffs to support consistent implementation across primary care and specialty settings. Analysts noted in client commentary that the launch signals rising competition as multiple assays try to drive broader adoption beyond PET imaging and cerebrospinal fluid testing. Labcorp expects nationwide availability in coming months, which could expand diagnostic access in routine care settings. The Elecsys pTau217 Plasma test strengthens a biomarker-led approach to Alzheimer’s staging, positioning blood assays as scalable triage tools prior to confirmatory evaluation.
-
Johnson & Johnson expands Imaavy to warm autoimmune hemolytic anemia
Johnson & Johnson’s Imaavy (isatuximab-irfc) secured a U.S. label expansion for warm autoimmune hemolytic anemia (wAIHA), making it the first FDA-approved therapy specifically for that rare indication. J&J framed the update as a continuation of the drug’s growing portfolio, after last year’s approval for generalized myasthenia gravis. Imaavy is an antibody therapy designed to target CD38 on immune cells, a mechanism intended to reduce autoantibody-driven red blood cell destruction in wAIHA. The label update gives clinicians an additional option in a disease area where treatment choices have historically been limited. The change also adds momentum for commercial planning across multiple autoimmune and neuromuscular indications. With wAIHA moving into the FDA-cleared lineup, payers and providers are expected to reassess treatment pathways. For biotech teams, the move underscores continued interest in immunology assets with label expansion potential beyond initial launches.
-
FDA grants humanitarian device exemption for bile duct cancer
The FDA awarded a humanitarian device exemption (HDE) approval to Oncosil Medical’s Oncosil brachytherapy device for distal cholangiocarcinoma. The decision makes Oncosil the first and only U.S. FDA-approved Class III device for this rare bile duct cancer indication, according to CEO Nigel Lange. Brachytherapy provides localized radiation delivery through implanted sources, and HDE status is intended for conditions affecting small patient populations where conventional approval pathways may be challenging. The HDE clearance supports Oncosil’s positioning for treatment programs in specialized oncology centers. The device approval also adds to the growing list of interventional oncology tools seeking to address hard-to-treat gastrointestinal malignancies. Hospitals and clinicians will now evaluate logistics, patient selection, and integration into existing care pathways. For investors and developers, the HDE outcome highlights how niche device programs can still progress to FDA clearance when clinical need and feasibility align.
-
Jazz and Actio strike $1.32B epilepsy acquisition
Jazz Pharmaceuticals agreed to acquire Actio Biosciences and its lead epilepsy drug ABS-1230 in a deal valued at about $1.32 billion. The acquisition expands Jazz’s epilepsy footprint amid persistent unmet need and continued pharma interest in seizure and neurologic disorder pathways. The transaction reflects a broader consolidation pattern in epilepsy, where companies are searching for differentiated clinical-stage candidates that can address efficacy and tolerability gaps. Jazz said the move brings ABS-1230 into its development pipeline earlier in the next phase of product planning. For Actio, the deal is a strategic exit that can accelerate clinical and regulatory work under Jazz’s resources. For Jazz, it offers potential optionality for diversification beyond the company’s current branded neurology portfolio. The timing suggests epilepsy remains a funding-and-M&A magnet where developers compete on mechanism, trial design, and patient subgroups.
-
Genentech and Hanmi expand obesity efforts with $190M upfront
Genentech, part of Roche, inked a metabolic pact with Hanmi Pharmaceutical to develop, manufacture, and commercialize HM-17321, a long-acting urocortin-2 (UCN2) analog. Genentech will pay Hanmi $190 million upfront, with total deal value potentially reaching about $2.3 billion including milestones and royalties. The arrangement gives Genentech worldwide rights to HM-17321 except for South Korea, where Hanmi retains full development and commercialization control. The program is designed to selectively reduce fat mass while preserving muscle mass and function, a differentiator aimed at avoiding the muscle loss concerns associated with some weight-loss therapies. HM-17321 received U.S. IND clearance in November 2025 for a Phase 1 study evaluating safety, tolerability, and pharmacokinetics/pharmacodynamics in healthy volunteers and people with obesity. Hanmi will complete Phase 1, after which Genentech takes over further development. The deal adds to Roche’s obesity portfolio and signals continued effort to broaden beyond incretin-centric mechanisms as companies seek differentiated efficacy and safety profiles.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.